Contact Us

Preimplantation genetic diagnosis is used for a broader range of indications, including chromosomal abnormalities, genetic abnormalities associated with adult onset disorders, rhesus incompatibility, human leukocyte antigens (HLA) tissue type, and intentionally selecting for medical conditions (deafness) and traits like sex.

Statistics:

The global preimplantation genetic diagnosis market is estimated to account for US$ 53.5 Mn in terms of value in 2020 and is expected to reach US$ 81.6 Mn by the end of 2027.

Global Preimplantation Genetic Diagnosis Market: Drivers

Rising rate of infertility is expected to propel growth of the global preimplantation genetic diagnosis market over the forecast period. For instance, according to the National Survey of Family Growth data published in September 2018, 15.5% of all women who intend to become pregnant are infertile and 6.7% of married women aged 15 to 44 years are infertile, in the U.S.

Global Preimplantation Genetic Diagnosis Market: Opportunities

R&D in genetics is expected to offer lucrative growth opportunities for players in the global preimplantation genetic diagnosis market. People want to be guilt free from giving the sufferings of genetic disorders to their children. Clinical progress in the IVF and preimplantation genetic diagnosis and the increasing knowledge in the medicine and molecular field associated with both male and female infertility and that in intracytoplasmic sperm injection will assist in growth of the global preimplantation genetic diagnosis market.

Global Preimplantation Genetic Diagnosis Market: Restraints

Scientific, ethical, and policy issues are expected to hinder growth of the global preimplantation genetic diagnosis market. There are quite a few issues persistent about the safety of the in vitro fertilization in preimplantation genetic diagnosis. The accuracy of these methods is also questioned by a few physicians and researchers. In addition, few people also find preimplantation genetic diagnosis as morally unacceptable because of involvement of unnatural creation and destruction of human embryo. There is a huge ethical issues regarding whether preimplantation genetic diagnosis should be adopted or not.

Key Takeaways:

The global preimplantation genetic diagnosis market was valued at US$ 50.3 Mn in 2019 and is forecast to reach a value of US$ 81.6 Mn by 2027 at a CAGR of 6.2% between 2020 and 2027. Major factor driving the growth of global preimplantation genetic diagnosis market during the forecast period include increasing incidences of genetic diseases, and increasing number of fertility centers.

Chromosomal Abnormalities held dominant position in the global preimplantation genetic diagnosis market in 2019, accounting for 20.1% share in terms of value, followed by X-linked diseases and Aneuploidy, respectively. Increasing prevalence of genetic disorders is supporting growth of the segment.

Market Trends

Major players in the global preimplantation genetic diagnosis market are focused on adopting partnership and collaboration strategies to enhance their market share. For instance, in October 2018, Illumina Inc. signed an agreement with Vitrolife AB under which Vitrolife act as a distributor supplier of Illumina’s PGT products in EMEA and America.

Major players in the global preimplantation genetic diagnosis market are also focused on adopting expansion strategies to enhance their market share. For instance, in June 2020, Natera, Inc. announced the expansion of its laboratory facility in Austin, Texas, supporting greater test processing capacity.

Global Preimplantation Genetic Diagnosis Market: Competitive Landscape   

Major players operating in the global preimplantation genetic diagnosis include, Amgen, Quest Diagnostics, Genentech Inc., Vertex, PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Abbott Laboratories, Illumina, Inc., Natera Inc., CooperGenomics Inc., Reproductive Genetics Institute, Inc., Genea Ltd., Invitae Corporation, and CombiMatrix Corporation.

Global Preimplantation Genetic Diagnosis Market: Key Developments

Major players in the global preimplantation genetic diagnosis market are focused on adopting various strategies to enhance their market share. For instance, in April 2019, Quest Diagnostics presented new insights from genetic testing at the 2019 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting, held in the U.S.

Segmentation

  • By Type
    • Chromosomal Abnormalities
    • Aneuploidy
    • X-linked diseases
    • Single gene disorders
    • HLA Typing
    • Gender Selection
    • Others (for disability, adult onset disease)
  • By End User
    • Diagnostic Laboratories
    • Hospitals
    • Clinics
  • By Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner